Vaspin inhibits kallikrein 7 by serpin mechanism

详细信息    查看全文

• 作者：John T. Heiker (1)
  Nora Kl?ting (2)
  Peter Kovacs (2)
  E. Bartholomeus Kuettner (3)
  Norbert Str?ter (3)
  Stephan Schultz (1)
  Matthias Kern (2)
  Michael Stumvoll (2)
  Matthias Blüher (2)
  Annette G. Beck-Sickinger (1)
  
• 关键词：Vaspin ; SerpinA12 ; Kallikrein 7 ; Crystal structure ; Diabetes ; Insulin
• 刊名：Cellular and Molecular Life Sciences (CMLS)
• 出版年：2013
• 出版时间：July 2013
• 年：2013
• 卷：70
• 期：14
• 页码：2569-2583
• 全文大小：1243KB
• 参考文献：1. James PT, Rigby N, Leach R (2004) The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil 11(1):3- CrossRef
  2. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, Hollenbeck A, Leitzmann MF (2006) Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71?years old. N Engl J Med 355(8):763-78 CrossRef
  3. Van Gaal LF, Mertens IL, De Block CE (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444(7121):875-80 CrossRef
  4. Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89(6):2548-556 CrossRef
  5. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PGW, Irving JA, Lomas DA, Luke CJ, Moyer RW, Pemberton PA, Remold-O’Donnell E, Salvesen GS, Travis J, Whisstock JC (2001) The serpins are an expanding superfamily of structurally similar but functionally diverse proteins—evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 276(36):33293-3296 CrossRef
  6. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto L, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H, Kanwar YS (2005) Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 102(30):10610-0615 CrossRef
  7. Kloting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M (2006) Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 339(1):430-36 CrossRef
  8. Kloting N, Kovacs P, Kern M, Heiker JT, Fasshauer M, Schon MR, Stumvoll M, Beck-Sickinger AG, Bluher M (2011) Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia 54(7):1819-823 CrossRef
  9. Brunetti L, Di Nisio C, Recinella L, Chiavaroli A, Leone S, Ferrante C, Orlando G, Vacca M (2011) Effects of vaspin, chemerin and omentin-1 on feeding behavior and hypothalamic peptide gene expression in the rat. Peptides 32(9):1866-871 CrossRef
  10. Teshigawara S, Wada J, Hida K, Nakatsuka A, Eguchi J, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, Iseda I, Matsushita Y, Miyatake N, McDonald JF, Hotta K, Makino H (2012) Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at SERPINA12 genetically defines distinct group with higher serum levels in Japanese population. J Clin Endocrinol Metab 97(7):E1202–E1207 CrossRef
  11. Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M, Bluher M (2008) Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 57(2):372-77 CrossRef
  12. Kabsch W (2010) Xds. Acta Crystallogr D Biol Crystallogr 66(Pt 2):125-32 CrossRef
  13. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ (2007) Phaser crystallographic software. J Appl Crystallogr 40(Pt 4):658-74 CrossRef
  14. Stein N (2008) CHAINSAW: a program for mutating pdb files used as templates in molecular replacement. J Appl Crystallogr 41:641-43 CrossRef
  15. Collaborative Computational Project N (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50(Pt 5):760-63 CrossRef
  16. Emsley P, Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2126-132 CrossRef
  17. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53(Pt 3):240-55 CrossRef
  18. Blanc E, Roversi P, Vonrhein C, Flensburg C, Lea SM, Bricogne G (2004) Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. Acta Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1):2210-221 CrossRef
  19. Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM, Kapral GJ, Murray LW, Richardson JS, Richardson DC (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66(Pt 1):12-1 CrossRef
  20. Schechter NM, Plotnick MI (2004) Measurement of the kinetic parameters mediating protease–serpin inhibition. Methods 32(2):159-68 CrossRef
  21. Kloting N, Koch L, Wunderlich T, Kern M, Ruschke K, Krone W, Bruning JC, Bluher M (2008) Autocrine IGF-1 action in adipocytes controls systemic IGF-1 concentrations and growth. Diabetes 57(8):2074-082 CrossRef
  22. Fisher SJ, Kahn CR (2003) Insulin signaling is required for insulin’s direct and indirect action on hepatic glucose production. J Clin Invest 111(4):463-68
  23. Kuttler B, Wanka H, Kloting N, Gerstmayer B, Volk HD, Sawitzki B, Ritter T (2007) Ex vivo gene transfer of viral interleukin-10 to BB rat islets: no protection after transplantation to diabetic BB rats. J Cell Mol Med 11(4):868-80 CrossRef
  24. Raile K, Klammt J, Laue S, Garten A, Bluher M, Kralisch S, Kloting N, Kiess W (2005) Glucose concentration and AMP-dependent kinase activation regulate expression of insulin receptor family members in rat islets and INS-1E beta cells. Diabetologia 48(9):1798-809 CrossRef
  25. Meyer-Hoffert U, Wu Z, Sreseli R, Ziernig E, BartelsHari J, Schwarz T, Schroder JM (2008) Purification and characterization of vaspin in human skin—a new epidermal serine protease inhibitor. Exp Dermatol 17(3):285
  26. Diamandis EP, Yousef GM (2001) Human tissue kallikrein gene family: a rich source of novel disease biomarkers. Exp Rev Mol Diagn 1(2):182-90 CrossRef
  27. Huntington JA, Read RJ, Carrell RW (2000) Structure of a serpin–protease complex shows inhibition by deformation. Nature 407(6806):923-26 CrossRef
  28. Schechter I, Berger A (1967) On the size of the active site in proteases I. Papain. Biochem Biophys Res Commun 27(2):157-62 CrossRef
  29. Loebermann H, Tokuoka R, Deisenhofer J, Huber R (1984) Human alpha-1-proteinase inhibitor—crystal structure analysis of 2 crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol 177(3):531-56 CrossRef
  30. Hopkins PCR, Stone SR (1995) The contribution of the conserved hinge region residues of alpha(1)-antitrypsin to its reaction with elastase. Biochemistry 34(48):15872-5879 CrossRef
  31. Zhou A, Carrell RW, Huntington JA (2001) The serpin inhibitory mechanism is critically dependent on the length of the reactive center loop. J Biol Chem 276(29):27541-7547 CrossRef
  32. Caso R, Lane DA, Thompson EA, Olds RJ, Thein SL, Panico M, Blench I, Morris HR, Freyssinet JM, Aiach M et al (1991) Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrate. Br J Haematol 77(1):87-2 CrossRef
  33. Hopkins PC, Carrell RW, Stone SR (1993) Effects of mutations in the hinge region of serpins. Biochemistry 32(30):7650-657 CrossRef
  34. Gettins P, Patston PA, Schapira M (1993) The role of conformational change in serpin structure and function. BioEssays 15(7):461-67 CrossRef
  35. Huber R, Carrell RW (1989) Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry 28(23):8951-966 CrossRef
  36. Hood DB, Huntington JA, Gettins PG (1994) Alpha 1-proteinase inhibitor variant T345R. Influence of P14 residue on substrate and inhibitory pathways. Biochemistry 33(28):8538-547 CrossRef
  37. Debela M, Magdolen V, Schechter N, Valachova M, Lottspeich F, Craik CS, Choe Y, Bode W, Goettig P (2006) Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J Biol Chem 281(35):25678-5688 CrossRef
  38. Skytt A, Stromqvist M, Egelrud T (1995) Primary substrate-specificity of recombinant human stratum–corneum chymotryptic enzyme. Biochem Biophys Res Commun 211(2):586-89 CrossRef
  39. Dong Y, Matigian N, Harvey TJ, Samaratunga H, Hooper JD, Clements JA (2008) Tissue-specific promoter utilisation of the kallikrein-related peptidase genes, KLK5 and KLK7, and cellular localisation of the encoded proteins suggest roles in exocrine pancreatic function. Biol Chem 389(2):99-09 CrossRef
  40. Johnson SK, Ramani VC, Hennings L, Haun RS (2007) Kallikrein 7 enhances pancreatic cancer cell invasion by shedding E-cadherin. Cancer 109(9):1811-820 CrossRef
  41. Korner A, Neef M, Friebe D, Erbs S, Kratzsch J, Dittrich K, Bluher S, Kapellen TM, Kovacs P, Stumvoll M, Bluher M, Kiess W (2011) Vaspin is related to gender, puberty and deteriorating insulin sensitivity in children. Int J Obes (London) 35(4):578-86 CrossRef
  42. Campbell DJ, Kladis A, Zhang Y, Jenkins AJ, Prior DL, Yii M, Kenny JF, Black MJ, Kelly DJ (2010) Increased tissue kallikrein levels in type 2 diabetes. Diabetologia 53(4):779-85 CrossRef
  43. Borgono CA, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, Sotiropoulou G, Diamandis EP (2007) A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J Biol Chem 282(6):3640-652 CrossRef
  44. Deraison C, Bonnart C, Lopez F, Besson C, Robinson R, Jayakumar A, Wagberg F, Brattsand M, Hachem JP, Leonardsson G, Hovnanian A (2007) LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell 18(9):3607-619 CrossRef
  45. Luo LY, Yousef G, Diamandis EP (2003) Human tissue kallikreins and testicular cancer. APMIS 111(1):225-32 CrossRef
  46. Prezas P, Arlt MJ, Viktorov P, Soosaipillai A, Holzscheiter L, Schmitt M, Talieri M, Diamandis EP, Kruger A, Magdolen V (2006) Overexpression of the human tissue kallikrein genes KLK4, 5, 6, and 7 increases the malignant phenotype of ovarian cancer cells. Biol Chem 387(6):807-11 CrossRef
  47. Yousef GM, Polymeris ME, Yacoub GM, Scorilas A, Soosaipillai A, Popalis C, Fracchioli S, Katsaros D, Diamandis EP (2003) Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 63(9):2223-227
  48. Saalbach A, Vester K, Rall K, Tremel J, Anderegg U, Beck-Sickinger AG, Bluher M, Simon JC (2012) Vaspin—a link of obesity and psoriasis? Exp Dermatol 21(4):309-12 CrossRef
  49. Duckworth WC, Bennett RG, Hamel FG (1998) Insulin degradation: progress and potential. Endocr Rev 19(5):608-24 CrossRef
  50. Kishi T, Soosaipillai A, Grass L, Little SP, Johnstone EM, Diamandis EP (2004) Development of an immunofluorometric assay and quantification of human kallikrein 7 in tissue extracts and biological fluids. Clin Chem 50(4):709-16 CrossRef
  51. Aust G, Richter O, Rohm S, Kerner C, Hauss J, Kloting N, Ruschke K, Kovacs P, Youn BS, Bluher M (2009) Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis 204(1):262-66 CrossRef
  52. Hida K, Poulsen P, Teshigawara S, Nilsson E, Friedrichsen M, Ribel-Madsen R, Grunnet L, Lund SS, Wada J, Vaag A (2012) Impact of circulating vaspin levels on metabolic variables in elderly twins. Diabetologia 55(2):530-32 CrossRef
  53. Buamah PK, Skillen AW (1985) Concentrations of protease and anti-protease in serum of patients with pancreatic cancer. Clin Chem 31(6):876-77
  54. Wiman B (2000) Discovery of PAI-1 in plasma. Thromb Res 100(1):7-
  55. Jeong E, Youn BS, Kim DW, Kim EH, Park JW, Namkoong C, Jeong JY, Yoon SY, Park JY, Lee KU, Kim MS (2010) Circadian rhythm of serum vaspin in healthy male volunteers: relation to meals. J Clin Endocrinol Metab 95(4):1869-875 CrossRef
  56. Teixeira TS, Freitas RF, Abrahao O Jr, Devienne KF, de Souza LR, Blaber SI, Blaber M, Kondo MY, Juliano MA, Juliano L, Puzer L (2011) Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7. Bioorg Med Chem Lett 21(20):6112-115 CrossRef
  57. Harper JW, Powers JC (1985) Reaction of serine proteases with substituted 3-alkoxy-4-chloroisocoumarins and 3-alkoxy-7-amino-4-chloroisocoumarins: new reactive mechanism-based inhibitors. Biochemistry 24(25):7200-213 CrossRef
  58. Dong Y, Tan OL, Loessner D, Stephens C, Walpole C, Boyle GM, Parsons PG, Clements JA (2010) Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Res 70(7):2624-633 CrossRef
  59. Mirsky IA, Broh-Kahn RH (1949) The inactivation of insulin by tissue extracts; the distribution and properties of insulin inactivating extracts. Arch Biochem 20(1):1-
  60. Perlmutter DH, Glover GI, Rivetna M, Schasteen CS, Fallon RJ (1990) Identification of a serpin–enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci USA 87(10):3753-757 CrossRef
  61. Perlmutter DH, Joslin G, Nelson P, Schasteen C, Adams SP, Fallon RJ (1990) Endocytosis and degradation of alpha 1-antitrypsin-protease complexes is mediated by the serpin–enzyme complex (SEC) receptor. J Biol Chem 265(28):16713-6716
  
• 作者单位：John T. Heiker (1)
  Nora Kl?ting (2)
  Peter Kovacs (2)
  E. Bartholomeus Kuettner (3)
  Norbert Str?ter (3)
  Stephan Schultz (1)
  Matthias Kern (2)
  Michael Stumvoll (2)
  Matthias Blüher (2)
  Annette G. Beck-Sickinger (1)
  
  1. Institute of Biochemistry, Faculty of Biosciences, Pharmacy and Psychology, Universit?t Leipzig, Brüderstra?e 34, Leipzig, 04103, Germany
  2. Department of Internal Medicine, Universit?t Leipzig, Liebigstr. 20, 04103, Leipzig, Germany
  3. Center for Biotechnology and Biomedicine, Institute of Bioanalytical Chemistry, Faculty of Chemistry and Mineralogy, Universit?t Leipzig, Leipzig, 04103, Germany
  
• ISSN：1420-9071

文摘

The molecular target of the adipokine vaspin (visceral adipose tissue-derived serpin; serpinA12) and its mode of action are unknown. Here, we provide the vaspin crystal structure and identify human kallikrein 7 (hK7) as a first protease target of vaspin inhibited by classical serpin mechanism with high specificity in vitro. We detect vaspin–hK7 complexes in human plasma and find co-expression of both proteins in murine pancreatic β-cells. We further demonstrate that hK7 cleaves human insulin in the A- and B-chain. Vaspin treatment of isolated pancreatic islets leads to increased insulin concentration in the media upon glucose stimulation without influencing insulin secretion. By application of vaspin and generated inactive mutants, we find the significantly improved glucose tolerance in C57BL/6NTac and db/db mice treated with recombinant vaspin fully dependent on the vaspin serpin activity and not related to vaspin-mediated changes in insulin sensitivity as determined by euglycemic-hyperinsulinemic clamp studies. Improved glucose metabolism could be mediated by increased insulin plasma concentrations 150?min after a glucose challenge in db/db mice, supporting the hypothesis that vaspin may inhibit insulin degradation by hK7 in the circulation. In conclusion, we demonstrate the inhibitory serpin nature and the first protease target of the adipose tissue-derived serpin vaspin, and our findings suggest hK7 inhibition by vaspin as an underlying physiological mechanism for its compensatory actions on obesity-induced insulin resistance.